OBJECTIVE: Broad antiinflammatory effects following adenosine A(₂A) receptor stimulation have been demonstrated in acute inflammatory diseases, including arthritis. Polydeoxyribonucleotide (PDRN) activates the adenosine A(₂A) receptor. This study was undertaken to investigate the effects of PDRN in collagen-induced arthritis (CIA) in mice. METHODS: Arthritis was induced in DBA/1 mice by an intradermal injection of 100 μl of bovine type II collagen in Freund's complete adjuvant. Mice were immunized a second time 21 days later. Control animals received 100 μl of a saline solution. Animals with CIA were randomized to receive one of the following: vehicle (1 ml/kg); PDRN (8 mg/kg intraperitoneally daily); 3,7-dimethyl-propargylxanthine (DMPX), a specific adenosine A(₂A) receptor antagonist (0.1 mg/kg intraperitoneally daily); or PDRN plus DMPX. The treatment was initiated immediately after the second immunization and continued to day 45. Clinical evaluation of arthritis was performed throughout the study. On day 45, the animals were killed and the severity of arthritis was evaluated histologically. Cartilage expression and circulating levels of high mobility group box chromosomal protein 1 (HMGB-1), tumor necrosis factor α (TNFα), interleukin-6 (IL-6), and IL-10 were investigated. Inflammatory cytokine production was also evaluated in stimulated human chondrocytes treated with PDRN. RESULTS: PDRN treatment significantly ameliorated clinical signs of arthritis, improved histologic damage, reduced the cartilage expression and circulating levels of HMGB-1, TNFα, and IL-6, and enhanced IL-10 expression. The concomitant administration of DMPX and PDRN ablated the PDRN-induced protective effect in experimental arthritis. PDRN also reduced cytokine production from stimulated human chondrocytes. CONCLUSION: Our findings indicate that PDRN may represent a new alternative for the treatment of arthritis.
OBJECTIVE: Broad antiinflammatory effects following adenosine A(₂A) receptor stimulation have been demonstrated in acute inflammatory diseases, including arthritis. Polydeoxyribonucleotide (PDRN) activates the adenosine A(₂A) receptor. This study was undertaken to investigate the effects of PDRN in collagen-induced arthritis (CIA) in mice. METHODS:Arthritis was induced in DBA/1 mice by an intradermal injection of 100 μl of bovine type II collagen in Freund's complete adjuvant. Mice were immunized a second time 21 days later. Control animals received 100 μl of a saline solution. Animals with CIA were randomized to receive one of the following: vehicle (1 ml/kg); PDRN (8 mg/kg intraperitoneally daily); 3,7-dimethyl-propargylxanthine (DMPX), a specific adenosine A(₂A) receptor antagonist (0.1 mg/kg intraperitoneally daily); or PDRN plus DMPX. The treatment was initiated immediately after the second immunization and continued to day 45. Clinical evaluation of arthritis was performed throughout the study. On day 45, the animals were killed and the severity of arthritis was evaluated histologically. Cartilage expression and circulating levels of high mobility group box chromosomal protein 1 (HMGB-1), tumor necrosis factor α (TNFα), interleukin-6 (IL-6), and IL-10 were investigated. Inflammatory cytokine production was also evaluated in stimulated human chondrocytes treated with PDRN. RESULTS: PDRN treatment significantly ameliorated clinical signs of arthritis, improved histologic damage, reduced the cartilage expression and circulating levels of HMGB-1, TNFα, and IL-6, and enhanced IL-10 expression. The concomitant administration of DMPX and PDRN ablated the PDRN-induced protective effect in experimental arthritis. PDRN also reduced cytokine production from stimulated human chondrocytes. CONCLUSION: Our findings indicate that PDRN may represent a new alternative for the treatment of arthritis.
Authors: Jonathan M Bekisz; Christopher D Lopez; Carmen Corciulo; Aranzazu Mediero; Paulo G Coelho; Lukasz Witek; Roberto L Flores; Bruce N Cronstein Journal: Inflammation Date: 2018-08 Impact factor: 4.092
Authors: Guohui Liu; X I Chen; W U Zhou; Shuhua Yang; Shunan Ye; Faqi Cao; Y I Liu; Yuan Xiong Journal: Exp Ther Med Date: 2016-02-17 Impact factor: 2.447
Authors: Pierluigi Bonfili; Pietro Franzese; Francesco Marampon; Maria Emilia La Verghetta; Silvia Parente; Manuela Cerasani; Daniela Di Genova; Marta Mancini; Francesca Vittorini; Giovanni Luca Gravina; Valeria Ruggieri; Mario Di Staso; Vladimir M Popov; Vincenzo Tombolini; Ernesto Di Cesare Journal: Support Care Cancer Date: 2013-12-10 Impact factor: 3.603
Authors: Jin-Hee Han; Junho Jung; Lakkyong Hwang; Il-Gyu Ko; Ok Hyung Nam; Mi Sun Kim; Jung-Woo Lee; Byung-Joon Choi; Deok-Won Lee Journal: Exp Ther Med Date: 2018-05-18 Impact factor: 2.447
Authors: Giovanni Pallio; Alessandra Bitto; Gabriele Pizzino; Federica Galfo; Natasha Irrera; Francesco Squadrito; Giovanni Squadrito; Socrate Pallio; Giuseppe P Anastasi; Giuseppina Cutroneo; Antonio Macrì; Domenica Altavilla Journal: Front Pharmacol Date: 2016-08-23 Impact factor: 5.810